NGT: Act Against Pharma Co. For Unsafe Disposal Of Biomed Waste

Chennai : The National Green Tribunal (NGT) has directed Tamil Nadu Pollution Control Board (TNPCB) to act against a Chennai-based pharma company for unsafe disposal of biomedical waste.

Inter Med, which has a tablet manufacturing unit in Porur, had dumped hazardous waste at a private land abutting Alapakkam Main Road. The corporation which spotted this violation collected a fine of ₹5,000 from the firm in August 2021.

But there was no follow-up action by the TNPCB. So, NGT Southern Zone, which was recently hearing a case pertaining to biomedical waste in Chennai, called this ‘unfortunate’ and directed the board to collect compensation from the firm.

During the hearing, GCC claimed that it had installed 50 CCTV cameras at vulnerable locations (of waste dumping) and a team at Ripon Buildings was monitoring the situation round the clock.

The civic body further told the tribunal that violators were booked under various provisions under the Biomedical Waste Management Rules, 2016 and in one such case (reported at Sri Lakshmi Nagar in Valasaravakkam) they had lodged a police complaint.

Besides this, the tribunal has told TNPCB to explore the possibility of tracing the total purchase and disposal of biomedical articles by healthcare units so that there is 100% transparency in the process. The NGT has given four months’ time to the board to submit a report regarding this.

At present, there are 4,240 healthcare facilities within the corporation limit, according to official data. All of them have obtained authorisation from the TNPCB to safely dispose of the biomed waste through agreements executed with two common biomedical waste treatment facilities.

  • Related Posts

    FDA seizes food stock worth Rs 63.45 crore, suspends 954 licences in two months

    The Maharashtra Food and Drug Administration (FDA) seized 3,098.46 tonnes of food stock worth Rs 63.45 crore and suspended 954 food licences during a statewide enforcement drive in the past…

    Stents to syringes: Serious harm reports surge, but makers remain unnamed

    6-year data disclosed first time by Indian Pharmacopoeia Commission on CIC order The Indian Pharmacopoeia Commission (IPC) has, for the first time, disclosed the number of Serious Adverse Events (SAEs)…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    FDA seizes food stock worth Rs 63.45 crore, suspends 954 licences in two months

    FDA seizes food stock worth Rs 63.45 crore, suspends 954 licences in two months

    Stents to syringes: Serious harm reports surge, but makers remain unnamed

    Stents to syringes: Serious harm reports surge, but makers remain unnamed

    NPPA Revises Retail and Ceiling Prices of 35 Drug Formulations; Fixes Prices of 34 New Drugs, Cholecalciferol, Oxaliplatin and Sun Pharma’s Diclofenac Gel

    NPPA Revises Retail and Ceiling Prices of 35 Drug Formulations; Fixes Prices of 34 New Drugs, Cholecalciferol, Oxaliplatin and Sun Pharma’s Diclofenac Gel

    ED attaches assets, freezes bank account in counterfeit medicines racket; searches five premises in Bengaluru

    ED attaches assets, freezes bank account in counterfeit medicines racket; searches five premises in Bengaluru

    Hyderabad Startup Working On Personalised Cancer Vaccine: What It Means For Cancer Treatment

    Hyderabad Startup Working On Personalised Cancer Vaccine: What It Means For Cancer Treatment

    Medicines that cure Us are making Our Environment Sick

    Medicines that cure Us are making Our Environment Sick